Search results for "bladder neoplasm"

showing 10 items of 158 documents

Expression of Female Sex Hormone Receptors, Connective Tissue Growth Factor and HER2 in Gallbladder Cancer

2019

AbstractGallbladder cancer (GBC) is a highly malignant tumor with poorly understood etiology. An insight into phenotypic features of this malignancy may add to the knowledge of its carcinogenesis and pave the way to new therapeutic approaches. We assessed the expression of female sex hormone receptors (ERα, ERβ, PR), connective tissue growth factor (CTGF) and HER2 in GBC, and adjacent normal tissue (NT), and determined their prognostic impact. Immunohistochemical (IHC) expression of all biomarkers was performed in formalin-fixed, paraffin-embedded specimens in 60 Caucasian GBC patients (51 women and 9 men). ERβ, cytoPR and CTGF expression were found in 89%, 27%, 91% of GBC, and in 63%, 87%,…

AdultMale0301 basic medicineReceptor ErbB-2Connective tissuelcsh:MedicinePathogenesismedicine.disease_causeArticleTumour biomarkersGastrointestinal cancer03 medical and health sciencesMedical research0302 clinical medicineBiomarkers TumorHumansMedicineGallbladder cancerReceptorlcsh:ScienceAgedAged 80 and overMultidisciplinarybusiness.industryGallbladderlcsh:RConnective Tissue Growth FactorGastroenterologyGallbladderMiddle AgedPrognosismedicine.diseaseCTGF030104 developmental biologymedicine.anatomical_structureOncologyRisk factorsHormone receptor030220 oncology & carcinogenesisCancer researchImmunohistochemistryFemaleGallbladder Neoplasmslcsh:QbusinessCarcinogenesisBiomarkersScientific Reports
researchProduct

Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder.

2003

BACKGROUND The differential expression patterns of cytokeratin 20 (CK20) and 34βE12 antigen in low-grade papillary urothelial tumors of the bladder are discussed. METHODS A retrospective study of 120 patients with low-grade papillary bladder tumors (45 neoplasms of low malignant potential and 75 low-grade WHO G1 carcinomas) was performed. All tumors were graded in accordance with the 1998 World Health Organization/International Society of Urological Pathology (WHO/ISUP) and 1999 WHO classifications. The mean follow-up was 76.6 months (range, 36–168 mos), considering for prognostic purposes the time to first recurrence, or relapse-free interval (RFI), and the total number of recurrent patien…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyKeratin-20Disease-Free SurvivalImmunoenzyme TechniquesCytokeratinAntigenIntermediate Filament ProteinsBladder NeoplasmCarcinomamedicineBiomarkers TumorHumansNeoplasm InvasivenessAgedNeoplasm StagingRetrospective StudiesAged 80 and overUrinary bladderbusiness.industryKeratin 20CancerMiddle Agedmedicine.diseasePrognosisCarcinoma PapillarySurvival Ratemedicine.anatomical_structureOncologyUrinary Bladder NeoplasmsDisease ProgressionImmunohistochemistryKeratinsFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesCancer
researchProduct

Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma.

2003

To study GP-170 in superficial bladder cancer at initial diagnosis and at recurrence and to evaluate if intravesical chemoprophylaxis modifies the expression of GP-170 in tumor recurrences. GP-170 was retrospectively assessed in 160 patients affected by primary superficial transitional cell carcinoma of the bladder and followed for up to 10 years. Eighty-four patients (52.5%) recurred after transurethral resection (TUR). Adjuvant intravesical chemotherapy after TUR was adopted in 52 patients. The correlations between GP-170 and G-grade, T-category, risk of recurrence and of progression, and adoption of adjuvant intravesical chemotherapy were investigated. The correlations between variations…

AdultMaleCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentUrologySettore MED/24 - UrologiaSuperficial bladder carcinoma GP-170 MDR-1 Prognosis Intravesical chemotherapyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansATP Binding Cassette Transporter Subfamily B Member 1Stage (cooking)AgedRetrospective StudiesChemotherapyHematologyUrinary bladderbusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePrognosisDrug Resistance MultipleGene Expression Regulation NeoplasticTransitional cell carcinomamedicine.anatomical_structureOncologyUrinary Bladder NeoplasmsChemotherapy AdjuvantDrug Resistance NeoplasmChemoprophylaxisFemaleSuperficial Bladder CarcinomaGenes MDRNeoplasm Recurrence LocalbusinessFollow-Up StudiesJournal of cancer research and clinical oncology
researchProduct

p53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder--a helpful parameter in guiding the decision for or again…

2000

The aim of this study was to determine whether p53 is helpful in making the decision to undergo cystectomy in T1, G3 transitional cell carcinoma (TCC) of the bladder, by prospectively comparing the p53 status of bladder biopsies with the histology and p53 status of the corresponding cystectomy specimens. From January 1996 to August 1997, 38 consecutive patients with T1G3 TCC at 6 different centres were enrolled into the study. Bladder biopsies and cystectomy specimens were examined with three different antibodies against p53. The p53 status of each bladder biopsy was compared with p53 status, tumour stage and grade of the cystectomy specimen. An independent evaluation of the histology and i…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBiopsyUrinary BladderUrologyCystectomyCystectomyBiopsymedicineHumansProspective StudiesAgedNeoplasm StagingCarcinoma Transitional CellBladder cancerUrinary bladdermedicine.diagnostic_testbusiness.industryHistologyMiddle Agedmedicine.diseaseImmunohistochemistrySurgeryTransitional cell carcinomamedicine.anatomical_structureOncologyUrinary Bladder NeoplasmsImmunohistochemistryHistopathologyFemaleTumor Suppressor Protein p53businessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

[Conservative treatment of locally advanced bladder carcinoma: neoadjuvant chemotherapy, TUR and radiotherapy. Results in 40 patients]

1998

to assess the results of bladder preservation in infiltrating bladder cancer. The potential for neoadjuvant chemotherapy followed by extensive TUR and radiotherapy was investigated in 40 patients with T2-T4a G2-G3 bladder carcinoma.from 1983 to 1995, 40 patients were submitted to bladder-sparing treatment consisting of neoadjuvant chemotherapy, extensive, TUR and radiotherapy. Most patients had T3G3 cancer. Cystectomy was not performed due to patient" choice in 29 cases (72.5%), for severe pulmonary or cardiovascular disease in disease in 9 patients (22.5) and age over 80 in 2 (5%) patients. A deep TUR-biopsy was performed before and after chemotherapy and an extensive TUR was repeated at t…

AdultMaleNeoplasm ResidualBiopsyCystectomyVinblastineAntineoplastic Combined Chemotherapy ProtocolsPreoperative CareHumansNeoplasm InvasivenessNeoplasm MetastasisAgedAged 80 and overNeoplasm InvasiveneAntineoplastic Combined Chemotherapy ProtocolRemission InductionMiddle AgedNeoplasm MetastasiMethotrexateUrinary Bladder NeoplasmsChemotherapy AdjuvantEvaluation Studies as TopicUrinary Bladder NeoplasmFemaleRadiotherapy AdjuvantCisplatinNeoplasm Recurrence LocalHuman
researchProduct

Factors affecting recurrence and progression in superficial bladder tumours

1995

Prognostic factors in superficial bladder tumours are highly correlated with each other. In this study, their relative importance is examined and grouping of patients in three different prognostic groups suggested. 576 patients (from EORTC protocols 30790 and 30782) were analysed. They have been followed from 3 months to 8.6 years with a median of 4 years. 76 patients developed an invasive tumour (or = T2); the shortest time to invasion was 12 weeks, the longest was 6.6 years. Time from invasion to death ranged from 3 weeks to 4.4 years with a median of 2 years. Prognostic factors contributing to recurrence, invasion and survival were investigated: age, sex, size of largest tumour, number o…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyTime FactorsMultivariate analysisAdolescentMalignant diseaseRisk groupsRisk FactorsInternal medicinemedicineCarcinomaHumansNeoplasm InvasivenessIn patientSurvival rateAgedAged 80 and overAnalysis of VarianceCarcinoma Transitional Cellbusiness.industryMiddle AgedPrognosismedicine.diseaseSurgerySurvival RateTransitional cell carcinomaUrinary Bladder NeoplasmsOncologyTumour sizeDisease ProgressionFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesEuropean Journal of Cancer
researchProduct

High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancer

2020

Abstract Background The cell surface interleukin 22 (IL-22) receptor complex is mainly expressed in epithelial and tissue cells like pancreatitis cells. Recent studies described that IL-22R was overexpressed in malignant diseases and was associated with a poor overall survival (OS). The role of IL-22RA1 gene expression in muscle invasive bladder cancer (MIBC) has not been investigated, yet. Objectives The aim of this study was to analyze the role of IL-22RA1 gene expression in patients with MIBC. Methods In a cohort of 114 patients with MIBC who underwent radical cystectomy, IL-22RA1 gene expression was analyzed with qRT-PCR and correlated with clinical parameters. Furthermore, Kaplan-Meier…

AdultMaleOncologymedicine.medical_specialtyReceptor complexUrologymedicine.medical_treatment030232 urology & nephrologyCystectomyCohort StudiesCystectomyInterleukin 2203 medical and health sciences0302 clinical medicineInternal medicineGene expressionBiomarkers TumormedicineHumansNeoplasm InvasivenessAgedAged 80 and overMuscle NeoplasmsBladder cancerProportional hazards modelbusiness.industryReceptors InterleukinMiddle AgedPrognosismedicine.diseaseSurvival RateUrinary Bladder NeoplasmsOncology030220 oncology & carcinogenesisCohortT-stageFemalebusinessFollow-Up StudiesUrologic Oncology: Seminars and Original Investigations
researchProduct

Cigarette Smoking and Drinking Water Source: Correlation with Clinical Features and Pathology of Superficial Bladder Carcinoma

2007

<i>Objective:</i> Water source and cigarette smoking are related to clinical characteristics and pathology of superficial transitional cell carcinoma of the bladder. <i>Methods:</i> Tumor number, dimension, G-grade, T-stage, recurrences, cigarette smoking and water supply were recorded in patients harboring Ta–T1 G1–3 transitional cell carcinoma of the bladder. <i>Results:</i> Of 577 patients, 61% had multiple and 36% recurrent tumors. Two hundred and forty-one patients (42%) were current smokers and 188 (33%) were former smokers. Bottled water was the only drinkable source for 249 (45%) patients, municipal water supply for 177 (32%), artesian wells for 3…

AdultMalePathologymedicine.medical_specialtyUrologyWater sourceRisk AssessmentCigarette smokingRecurrenceRisk FactorsWater SupplyOdds RatioCarcinomaHumansMedicineWater PollutantsAgedNeoplasm StagingAged 80 and overCarcinoma Transitional CellBladder cancerbusiness.industrySmokingdigestive oral and skin physiologyOdds ratioMiddle Agedmedicine.diseaseTransitional cell carcinomaItalyUrinary Bladder NeoplasmsMultivariate AnalysisFemaleNeoplasm stagingSuperficial Bladder CarcinomabusinessUrologia Internationalis
researchProduct

Behavior of Epithelial Differentiation Antigens (Carcinoembryonic Antigen, Epithelial Membrane Antigen, Keratin and Cytokeratin) in Transitional Cell…

1992

Results of an immunohistochemical study in normal urothelium and transitional cell carcinomas of the bladder are presented. Paraffin-embedded material was confronted with immunoantisera against carcinoembryonic antigen (CEA), keratin (K), cytokeratin (CK) and epithelial membrane antigen (EMA). Immunohistochemical findings confirm the changes in reactivity of dysplastic urothelium and carcinoma in situ for CEA, CK and EMA, in comparison with normal urothelium. Statistically significant differences were also found, depending upon tumor stage, in staining of transitional cell carcinomas for K and CK. Expression of CK correlated with the tumor differentiation grade: normal urothelium and well-d…

AdultMalePathologymedicine.medical_specialtyUrologyurologic and male genital diseasesEpitheliumCytokeratinCarcinoembryonic antigenAntigenAntigens NeoplasmKeratinBiomarkers TumormedicineHumansUrotheliumAgedNeoplasm Stagingchemistry.chemical_classificationCarcinoma Transitional CellMembrane GlycoproteinsbiologyMucin-1Middle Agedmedicine.diseaseAntigens Differentiationfemale genital diseases and pregnancy complicationsCarcinoembryonic AntigenTransitional cell carcinomaUrinary Bladder Neoplasmschemistrybiology.proteinKeratinsImmunohistochemistryFemaleCarcinoma in SituImmunostainingUrologia Internationalis
researchProduct

Lymph Node Metastases in Non-Muscle Invasive Bladder Cancer are Correlated With the Number of Transurethral Resections and Tumour Upstaging at Radica…

2005

The first paper in this section, from Mainz, attempts to identify the clinical variables associated with the prevalence of lymph node metastases in non-muscle invasive bladder cancer. The authors found that delay in cystectomy in this potentially dangerous type of tumour is to be avoided, with a higher incidence of lymph node metastases as the number of transurethral resections increases. A paper from Austria shows that in renal carcinoma the pT1 subdivision is associated with differences in conventional histopathology and expression of biomarkers. OBJECTIVE To identify clinical variables associated with the prevalence of lymph node metastases (LNMs) in patients with non-muscle invasive tra…

AdultMaleReoperationmedicine.medical_specialtyMultivariate analysisUrologymedicine.medical_treatmentUrologyCystectomyCystectomyCarcinomamedicineAdjuvant therapyHumansLymph nodeAgedNeoplasm StagingRetrospective StudiesAged 80 and overCarcinoma Transitional CellBladder cancerbusiness.industryIncidence (epidemiology)Middle Agedmedicine.diseaseSurgeryUrethraTransitional cell carcinomamedicine.anatomical_structureUrinary Bladder NeoplasmsLymphatic MetastasisFemaleHistopathologybusinessJournal of Urology
researchProduct